MOB015B

Phase 3Small molecule

MMoberg Pharma AB

MOB015B is one of 2 small molecule programs targeting Onychomycosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OnychomycosisActive, not recruiting

OnychomycosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Onychomycosis

#DrugCompanyPhaseTrials

MOB015B

MMoberg Pharma AB

Phase 3

1 2

Trichostatin a

VVanda Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Completed·MMoberg Pharma AB·Phase 3·NCT02859519·365 enrolled

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Completed·MMoberg Pharma AB·Phase 3·NCT02866032·452 enrolled

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Completed·MMoberg Pharma AB·Phase 2·NCT01814020

Irritation1 trial

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Completed·MMoberg Pharma AB·Phase 1·NCT06369675·45 enrolled

Absorption1 trial

A Study of the Systemic Absorption of MOB015B

Completed·MMoberg Pharma AB·Phase 1·NCT03244280·20 enrolled

TIA1 trial

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

Completed·MMoberg Pharma AB·Phase 1·NCT06369727·250 enrolled

Onychomycosis1 trial

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Active, not recruiting·MMoberg Pharma AB·Phase 3·NCT05279846·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MOB015B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MOB015B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MOB015B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moberg Pharma AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMoberg Pharma AB

MOB015B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety3 trials

Irritation1 trial

Absorption1 trial

TIA1 trial

Onychomycosis1 trial

References

Drug Info

Quick Facts

Related News